source
- Revolution Medicines shares promising data around KRAS drug combinationRevolution Medicines on Thursday gave a first look at the early-stage data that led it to plan a Phase 3 trial combining two KRAS drugs in pancreatic cancer. One of the two drugs is a ...Endpoints · 27d ago↗ source
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.BioPharma Dive · 27d ago↗ source
- Otsuka reports long-term kidney data key to Voyxact's bid for full approvalOtsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease. The company said the Phase 3 study showed Voyxact stabiliz…